Navigation Links
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Date:5/12/2008

Presentation of Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week

2008

PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it has initiated the Phase 2 clinical development program of MDX-1100, a fully human monoclonal antibody that targets CXCL10 (also known as IP-10), in ulcerative colitis (UC) and rheumatoid arthritis (RA). MDX-1100 could potentially treat UC and RA by suppressing the inflammatory process characteristic of these diseases.

"Based on positive safety data in Phase 1 studies, we have initiated patient enrollment in Phase 2 studies that are designed to establish proof-of-concept," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are optimistic about the broad potential of MDX-1100 to address a range of inflammatory diseases."

Patients in the Phase 2 randomized, double-blind, placebo-controlled, multi-center study in UC will be administered MDX-1100 at 10 mg/kg or placebo every 2 weeks for a total of 4 doses. All patients will have active UC and will continue standard UC therapy during the trial. The trial is expected to enroll 106 patients at multiple sites internationally. The primary endpoint of the study is the response rate at 8 weeks. Clinical response is based on the Mayo score, a composite endpoint that assesses stool frequency and the amount of bloody stool per day as recorded in a patient diary, physician global assessment and the assessment of colon mucosal inflammation ascertained by endoscopy.

Patients in the Phase 2 randomized, double-blind, placebo-controlled, multi-center study in RA will be administered MDX-1100 at 10 mg/kg or placebo every 2
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market survey ... industry . The report firstly reviews the basic ... application and manufacturing technology. The report then explores ... Scanner listing their product specification, capacity, Production value, ...
(Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements ... the SAM Junctional Tourniquet.  Photo ... Medical Products announced today that it has begun ... a potential issue with a clip used to ... application of the SAM Junctional Tourniquet (SJT).  The ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... , GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- ... release financial results for the fiscal fourth quarter and full ... The company will host a conference call for investors on ... may access the live call by dialing 877-941-9205 (within the ...
... , HARRISBURG, Pa., Nov. 20 The Department of Health ... that did not have previous access to the vaccine. , A total ... hours are from 2 p.m. to 8 p.m. Hours on Saturday, Nov. ... the clinics will operate from 2 p.m. to 8 p.m. , ...
Cached Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2
(Date:9/1/2014)... Texas (PRWEB) September 02, 2014 “Australia ... data on the Australia Hernia Repair market. The report ... units) and average prices (in US dollars) within market ... Meshes and Synthetic 3D Meshes) ,     Composite Meshes ... to a surgical operation for the correction of a ...
(Date:9/1/2014)... with action and sound may be bad for your ... grapes while watching an excerpt from a Hollywood action ... Television has been blamed for helping Americans to gain ... focus of why has been on the medium and ... that can cause people to eat more, including reading, ...
(Date:9/1/2014)... Reinberg HealthDay Reporter ... head-to-head comparison, an experimental drug was more effective than ... failure patients. According to the study authors, the ... of the new drug, dubbed LCZ696. In ... medication, enalapril (Vasotec), either died or were hospitalized due ...
(Date:9/1/2014)... York (PRWEB) September 01, 2014 Liver is ... one vital organ that helps the body in barring itself ... a store of energy. Liver also plays many important functions ... iron and glucose. , Many illnesses can affect the ... under the rib cage on the right side of the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 More than ... added to a federal litigation that continues to progress ... Bernstein Liebhard LLP reports. , A federal Case ... filed over the widely-used cholesterol medication by plaintiffs who ... According to claims, Pfizer Inc. failed to adequately warn ...
Breaking Medicine News(10 mins):Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 2Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 3Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 4Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3
... The infant mortality rate in Orissa would continue to soar ... Suni Naik’s family is still trying to recover after losing ... delivery. // ,Speaking at Talchampei village in tribal-dominated Keonjhar ... They suffered from fever. I took Rs.1,000 from a moneylender ...
... A report published in the January/February issue of General ... journal, says that most children's medicines have the potential ... sugar in them. // ,For example, antihistamine syrups ... low pH levels, which mean that they are high ...
... it has been shown that tomato juice prevented emphysema in ... of the lung-destroying disease. // ,The lung protective ... ,This study appears to be the first to link tomato ... by the researchers, 'We can't simply accept that these results ...
... is greatly increased if an individual has a variant form ... tongue // . The taste receptor gene, called TAS2R16 is ... Washington University School of Medicine have studied more than 262 ... family participated in a study called Collaborative Study of the ...
... his team from University of California, San Francisco using ... sickle cell anemia // in bioengineered mice with healthy ... genes, after therapy it was found that the replaced ... published their work in the Journal Proceedings of the ...
... Department of Health and Human Services reported that very little ... of the illness (bird flu) // . The infection in ... avian influenza. ,Hence to prevent the global pandemic ... of an occurrence of a global pandemic. The government ...
Cached Medicine News:Health News:Poverty Claims Valuable Lives Of Children In Orissa 2Health News:Genetic Variation In Bitter-Taste Receptor Gene Increases Alcoholic Risk 2